Exclusive: 77 Former DOJ Officials Urge Senate To Confirm Todd Blanche As Attorney General:
‘His exemplary record … demonstrates he is the right man for the right time,’ the letter from the former high-ranking officials states.
Todd Blanche is “the right man for the right time,” a letter from 77 former Department of Justice officials declares in urging the Senate Judiciary Committee to support President Donald Trump’s pick to serve as the 88th U.S. Attorney General.
The former high-ranking DOJ officials — spanning multiple administrations — sent the letter Sunday to Senate Judiciary Chairman Chuck Grassley, R-Iowa, and Ranking Member Sen. Dick Durban, D-Ill., in advance of Blanche’s confirmation hearing, beginning Wednesday morning.
Blanche has served as acting U.S. attorney general since early April, following Attorney General Pam Bondi’s abrupt departure.
“His exemplary record as Deputy Attorney General — and now as Acting Attorney General — demonstrates he is the right man for the right time,” states the letter signed by dozens of former DOJ deputies, assistant AGs, U.S. attorneys, and others. The group includes Gary Barnett, former acting chief of staff and senior counselor to the attorney general; Ketan Bhirud, former associate deputy attorney general; Rachel Bissex, former deputy chief of staff and counselor to the attorney general; and Jonathan D. Brightbill, former acting assistant attorney general.
The recommendation notes Blanche’s rise up the ranks, beginning with his service with the DOJ as a paralegal in the Criminal Division and at the United States Attorney’s Office for the Southern District of New York. He did so while going to law school at night and supporting his young family, the letter states. He went on to become an assistant U.S. attorney in the SDNY’s violent-crimes division, “where he prosecuted serious offenses for eight years,” ultimately serving as co-chief of the unit. He “supervised dozens of prosecutors handling murder, kidnapping, and other violent crimes.”
“This hands-on experience as both a line prosecutor and supervisor gives him an unparalleled understanding of how the Department actually operates — from the streets to headquarters,” the letter asserts.
‘Clarity and Resolve’
A Trump loyalist, Blanche successfully served as the president’s legal counsel during the left’s relentless lawfare campaigns against Trump and his allies — political witch hunts stopping at nothing to stop the businessman’s return to the White House. Blanche began Trump’s second term as the DOJ’s deputy attorney general.
As the letter notes, in his role as acting AG, Blanche has overseen the day-to-day operations of a department with more than 100,000 employees in the main DOJ office, the FBI, the DEA, U.S. Marshals, ATF, and 93 U.S. Attorneys’ Offices.
“Under his leadership, the Department has advanced President Trump’s core priorities with clarity and resolve: confronting illegal immigration and dismantling the transnational criminal organizations that exploit our borders; combating the fentanyl crisis and violent crime that devastate American communities; and protecting taxpayers through aggressive fraud enforcement,” the letter states.
Blanche “launched the National Fraud Enforcement Division, which has already driven the recovery of billions of dollars stolen from programs like Medicare and COVID relief, while prioritizing the prosecution of those who prey on American taxpayers,” the support letter states.
‘He Knows What Works’ --->READ MORE HERE
Todd Blanche Can End Biden’s Illegal Mail-Order Abortion Scheme Now:
Blanche could resolve the problem immediately by settling the case and agreeing to a court-ordered consent decree. So far, he hasn’t done so.
Everybody has been waiting for the Food and Drug Administration to finish its safety review of the abortion drug mifepristone. This study, prompted by evidence that the drugs are more dangerous to women than previously supposed, is meant to inform changes the administration might make to the drug’s long-term FDA regulations. Reporting suggests that the study is now seriously underway and on track, which is welcomed news. However, any subsequent regulations are likely to be challenged in court by the abortion lobby and subject to lengthy litigation.
In the meantime, there’s another decision of utmost importance the administration has to make about abortion drugs — one that relies not on the FDA, but on Acting Attorney General Todd Blanche, who has been nominated as attorney general and awaits confirmation in the Senate. That’s the decision about whether, before the study is completed and the long-term regulations are set, we should still follow the Biden rules that everyone involved (other than the abortion industry, that is) admits are both dangerous and illegal.
The question is before the administration right now, thanks to a lawsuit brought by Louisiana and one of the growing cohort of survivors of Biden’s abortion-drug regime. The lawsuit seeks to reverse Biden’s rule changes allowing abortion drugs to be prescribed over the internet, without an in-person medical exam.
The DOJ does not contest the core of the lawsuit’s argument: the Biden rules were implemented in a way that violated the Administrative Procedure Act and are therefore unlawful. In fact, as the court found, the administration has basically said as much already.
Since they seem to agree on the merits, the DOJ led by Acting AG Blanche could resolve the whole problem immediately by simply settling the case and agreeing to a court-ordered consent decree. So far, however, they haven’t done so.
Instead, in addition to a few weak standing arguments that the courts have rejected, the administration has argued that, even if they’re illegal, the Biden rules should stay in place because the FDA’s safety review is still ongoing. This has been the administration’s line in general: Biden’s rules, they say, must stay in place until the study is complete.
Citing the review as a reason for keeping the Biden regulations makes no sense. In the first place, it confuses the issues at hand. The study is meant to inform any future regulations and to help the FDA make its medical judgments. But the question about the pre-existing Biden rules, and whether they violate the Administrative Procedure Act, is a legal question. It doesn’t need a study to back it up. --->READ MORE HERE
If you like what you see, please "Like" and/or Follow us on FACEBOOK
here, GETTR
here, and TWITTER
here.
No comments:
Post a Comment